In-Vivo Editing for Inherited Blindness: A Comprehensive Review for Clinical Practice

Abstract

Inherited blindness, representing a spectrum of genetically driven ocular disorders, has long posed significant therapeutic challenges due to the complexity of underlying genetic mutations and the limited efficacy of conventional treatments. Recent breakthroughs in gene-editing technologies, particularly in-vivo approaches such as CRISPR/Cas systems, have redefined the therapeutic landscape by enabling targeted correction of pathogenic mutations within the eye. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic strategies, and management of inherited blindness, with a special focus on in-vivo gene editing. The article critically examines the mechanisms, clinical trial outcomes, emerging therapies, and guideline recommendations, offering practical insights for clinicians engaged in the care of patients with inherited retinal dystrophies.

Introduction

Inherited blindness encompasses a group of ocular disorders primarily caused by monogenic mutations affecting retinal function. The most common entities include retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease, and choroideremia. Traditional management strategies have been largely supportive, with limited ability to alter disease progression. The advent of in-vivo gene editing has heralded a paradigm shift, offering hope for durable vision restoration by directly correcting genetic defects in retinal cells. This review aims to provide clinicians with a comprehensive understanding of the current landscape and future prospects of in-vivo editing for inherited blindness, grounded in the latest scientific and clinical evidence.

Epidemiology / Disease Burden

Inherited retinal diseases (IRDs) collectively affect approximately 1 in 3,000 to 4,000 individuals worldwide. Among these, RP is the most prevalent, accounting for nearly 50% of all IRDs. The disease burden is substantial, with early-onset forms often resulting in childhood blindness and considerable socioeconomic impact on affected individuals and their families. Geographic and ethnic variations in prevalence are observed, influenced by founder mutations and consanguinity rates. The progressive nature of these disorders underlines the urgent need for effective, disease-modifying interventions, particularly in cases where blindness occurs before adulthood.

Pathophysiology

Inherited blindness arises from mutations in genes critical for photoreceptor development, function, or survival. These mutations can disrupt the visual cycle, affect phototransduction pathways, or lead to structural protein defects within the retina. For instance, in LCA, pathogenic variants in genes such as RPE65 or CEP290 impair the conversion of light into electrical signals, culminating in profound vision loss. The retina’s immune-privileged status and non-dividing nature make it an attractive target for in-vivo gene editing, as corrected cells persist for extended periods. However, the heterogeneity of mutations, modes of inheritance, and variable expressivity complicate therapeutic design and necessitate precise, personalized interventions.

Risk Factors

Primary risk factors for inherited blindness include a positive family history, consanguinity, and the presence of specific pathogenic variants within known IRD genes. Autosomal recessive inheritance predominates, although autosomal dominant and X-linked patterns are also observed. Environmental modifiers, such as light exposure or metabolic stress, may influence disease onset and progression but are secondary to genetic determinants. Advances in next-generation sequencing have enhanced risk stratification by enabling comprehensive carrier detection and pre-symptomatic diagnosis in at-risk individuals.

Clinical Features

Clinical manifestations of inherited blindness vary according to the underlying genetic defect. Common symptoms include progressive loss of night vision, peripheral visual field constriction, central acuity decline, and impaired color discrimination. Syndromic forms may present with associated systemic features such as hearing loss, renal dysfunction, or neurodevelopmental delay. Disease onset ranges from infancy (e.g., LCA) to adulthood (e.g., late-onset RP). Fundoscopic examination often reveals characteristic findings such as bone-spicule pigmentation, attenuated retinal vessels, and optic disc pallor in RP. Functional deficits are corroborated by electrophysiological testing, including electroretinography (ERG).

Diagnosis

Diagnosis of inherited blindness is predicated on a combination of clinical, imaging, and molecular approaches. Detailed ophthalmic evaluation, including visual acuity testing, visual field analysis, fundus photography, optical coherence tomography (OCT), and ERG, delineates the extent and pattern of retinal dysfunction. Definitive diagnosis hinges on molecular genetic testing, with targeted gene panels or whole exome/genome sequencing identifying causative mutations. Genetic counseling is integral for patient and family education, risk assessment, and informed decision-making regarding therapeutic interventions.

Treatment & Management

Historically, management of inherited blindness has focused on visual rehabilitation, low vision aids, and supportive care. The approval of voretigene neparvovec-rzyl, an in-vivo gene therapy for RPE65-mediated LCA, marked a significant milestone, demonstrating that gene augmentation can restore visual function in selected patients. However, most IRDs remain untreatable with conventional modalities. Pharmacological interventions, such as vitamin A supplementation, have shown limited benefit and are not universally applicable. The advent of in-vivo genome editing offers the potential to correct pathogenic mutations at their source, with implications for durable disease modification and vision restoration.

Recent Advances / Emerging Therapies

In-vivo gene editing technologies, notably CRISPR/Cas9, base editors, and prime editors, have emerged as transformative tools for ocular therapeutics. Clinical trials such as BRILLIANCE (EDIT-101) are evaluating the safety and efficacy of in-vivo CRISPR/Cas9-mediated editing for CEP290-associated LCA10, showing early signals of efficacy and manageable safety profiles. These approaches employ adeno-associated viral (AAV) vectors to deliver gene-editing machinery directly to retinal cells. Base editing and prime editing systems offer the advantage of precise nucleotide correction with reduced off-target risks. Additionally, antisense oligonucleotides and RNA-guided therapies are under investigation for specific splicing defects. Challenges remain, including immune responses, delivery efficiency, long-term durability, and ethical considerations, but the therapeutic potential is unprecedented.

Guideline Recommendations

International guidelines recommend genetic testing for all patients with suspected IRDs to guide prognosis, counseling, and eligibility for gene-targeted therapies. The American Academy of Ophthalmology and related bodies endorse the use of gene therapy in patients with confirmed biallelic RPE65 mutations. Enrolment in clinical trials is encouraged for patients with other genetically defined IRDs, given the rapidly evolving therapeutic landscape. Multidisciplinary management involving ophthalmologists, geneticists, and low vision specialists is essential for optimal patient care. Ongoing surveillance for long-term safety and efficacy of gene-editing interventions is mandated by regulatory agencies.

Conclusion

In-vivo editing has revolutionized the field of inherited blindness, offering the prospect of durable and potentially curative interventions for previously untreatable disorders. While early clinical results are promising, challenges related to delivery, immunogenicity, and long-term outcomes remain to be addressed. Continuous advancements in gene-editing technology, coupled with robust clinical trial data and clear guidelines, are poised to transform the standard of care for patients with inherited retinal diseases. Clinicians must remain abreast of these developments to provide informed, evidence-based guidance and optimize patient outcomes.